What is the recommended dose of Intravenous Immunoglobulin (IVIG) in autoimmune encephalitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IVIG Dosing in Autoimmune Encephalitis

The recommended dose of IVIG in autoimmune encephalitis is 2 g/kg divided over 5 days (0.4 g/kg/day for 5 consecutive days), particularly for severe or progressive cases. 1

Severity-Based Treatment Algorithm

Mild to Moderate Autoimmune Encephalitis

  • Initial treatment should be methylprednisolone 1-2 mg/kg/day IV without immediate IVIG 1, 2
  • IVIG is reserved for cases that fail to improve or progress despite corticosteroids 1

Severe or Progressive Autoimmune Encephalitis

  • IVIG 2 g/kg total dose divided over 5 days (0.4 g/kg/day) should be administered concurrently with pulse-dose methylprednisolone (1 g IV daily for 3-5 days) 1
  • This combination is specifically indicated when:
    • Symptoms are severe or rapidly progressing 1
    • Oligoclonal bands are present in CSF 1
    • Patient has confirmed autoimmune encephalopathy or paraneoplastic antibodies 1
    • No improvement after initial corticosteroid trial 1

Maintenance Therapy Considerations

  • For immune-mediated neurological conditions requiring ongoing treatment, maintenance IVIG is typically administered at ≥1 g/kg every 4 weeks 3
  • This maintenance dosing applies to patients with persistent or relapsing autoimmune encephalitis who have responded to initial therapy 3

Critical Implementation Details

Timing and Administration

  • IVIG should be initiated early in severe cases, not delayed while awaiting antibody confirmation 1
  • The 2 g/kg total dose is divided equally: 0.4 g/kg/day for 5 consecutive days 1, 4
  • A prospective trial demonstrated significant neurological improvement by day 8 with this dosing regimen 4

Alternative Dosing in Specific Contexts

  • Some protocols describe "2 doses at 1 g/kg/dose" for pediatric encephalitis, which equals the same 2 g/kg total 5
  • This represents the same cumulative dose administered over fewer days 5

Essential Caveats and Pitfalls

Infectious Exclusion

  • Always initiate empiric IV acyclovir until HSV PCR results are negative before or concurrent with IVIG 1, 2
  • Rule out bacterial meningitis, metabolic derangements, and CNS malignancy progression 1

Safety Monitoring

  • Patients with autonomic dysfunction are at higher risk for aseptic meningitis and severe headaches with IVIG 3
  • Monitor for thromboembolic complications, particularly in patients with risk factors 6
  • Anaphylactic reactions can occur in IgA-deficient patients with anti-IgA antibodies 7

Escalation Strategy

  • If no improvement after IVIG plus pulse corticosteroids, consider plasmapheresis or rituximab in consultation with neurology 1, 2
  • Corticosteroid taper should occur over at least 4-6 weeks following acute management 1

Evidence Quality Note

The 2 g/kg over 5 days dosing is consistently recommended across multiple ASCO guidelines from 2018 and 2021 1, with prospective evidence from a 2022 trial demonstrating efficacy and tolerability at 0.4 g/kg/day for 5 days 4. While most evidence comes from immune checkpoint inhibitor-related encephalitis, the dosing principles apply broadly to autoimmune encephalitis of all etiologies 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Methylprednisolone Dosing in Autoimmune Encephalitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

IVIG Therapy for Autoimmune Small Fiber Neuropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis.

Annals of clinical and translational neurology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.